Trending NewsTrending NewsNASDAQ:BBOT BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis $4.95 -0.57 (-10.33%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$5.01 +0.06 (+1.31%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BBOT alerts:Sign Up Key Stats Today's Range$4.90▼$5.6250-Day Range$4.95▼$9.6052-Week Range$4.90▼$14.87Volume1.63 million shsAverage Volume431,972 shsMarket Capitalization$396.84 millionP/E RatioN/ADividend YieldN/APrice Target$22.88Consensus RatingModerate Buy Company Overview BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need. BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development. Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here. Prospective investors and researchers should consult the company’s SEC filings, investor presentations and official disclosures for up-to-date details on its pipeline, management team and strategic priorities.AI Generated. May Contain Errors. Read More BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreBBOT MarketRank™: BridgeBio Oncology Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 385th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBridgeBio Oncology Therapeutics has a consensus price target of $22.88, representing about 362.1% upside from its current price of $4.95.Amount of Analyst CoverageBridgeBio Oncology Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Oncology Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Oncology Therapeutics are expected to grow in the coming year, from ($2.79) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Oncology Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Oncology Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBridgeBio Oncology Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.22% of the float of BridgeBio Oncology Therapeutics has been sold short.Short Interest Ratio / Days to CoverBridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 20.77, which indicates bearish sentiment.Change versus previous monthShort interest in BridgeBio Oncology Therapeutics has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Oncology Therapeutics does not currently pay a dividend.Dividend GrowthBridgeBio Oncology Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.09 News SentimentBridgeBio Oncology Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for BBOT on MarketBeat in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Oncology Therapeutics' insider trading history. Receive BBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBOT Stock News HeadlinesBridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS PlaybookSeptember 12 at 7:17 AM | finance.yahoo.comBridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low After Analyst DowngradeSeptember 12 at 4:45 AM | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 12 at 1:00 AM | Awesomely (Ad)BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Reaches New 52-Week Low Following Analyst DowngradeSeptember 12 at 4:04 AM | americanbankingnews.comLeerink Partners Issues Pessimistic Forecast for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock PriceSeptember 12 at 3:23 AM | americanbankingnews.comBridgeBio Oncology Therapeutics (NASDAQ:BBOT) Lowered to Strong Sell Rating by Wall Street ZenSeptember 12 at 1:18 AM | americanbankingnews.comWedbush Reiterates Outperform Rating for BridgeBio Oncology Therapeutics (NASDAQ:BBOT)September 11 at 1:18 AM | americanbankingnews.comBBOT Reports BBO-8520 Data in NSCLC, Highlights Combination ResultsSeptember 8, 2026 | marketscreener.comMSee More Headlines BBOT Stock Analysis - Frequently Asked Questions How have BBOT shares performed this year? BridgeBio Oncology Therapeutics' stock was trading at $11.50 at the beginning of 2026. Since then, BBOT shares have decreased by 57.0% and is now trading at $4.95. How were BridgeBio Oncology Therapeutics' earnings last quarter? BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) posted its quarterly earnings data on Tuesday, August, 11th. The company reported ($705.20) earnings per share for the quarter. Who are BridgeBio Oncology Therapeutics' major shareholders? Top institutional shareholders of BridgeBio Oncology Therapeutics include Wellington Management Group LLP (3.48%), Opaleye Management Inc. (0.87%), Tema ETFs LLC (0.12%) and Tidal Investments LLC (0.12%). How do I buy shares of BridgeBio Oncology Therapeutics? Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 2 days ago, BBOT's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BBOT CIK1869105 Webbbotx.com Phone(857) 702-0377FaxN/AEmployeesN/AYear Founded2025Price Target and Rating Average Price Target for BridgeBio Oncology Therapeutics$22.88 High Price Target$29.00 Low Price Target$15.00 Potential Upside/Downside+362.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.90% Return on Assets-42.17% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book0.96Miscellaneous Outstanding Shares80,170,000Free Float60,612,000Market Cap$396.84 million OptionableN/A Beta0.38 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:BBOT) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe income “unicorn” Todd Phillips has been waiting 2 years to see againRetirement income specialist Todd Phillips once tracked an unusual income vehicle nicknamed the 10.3 percent U...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Oncology Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Oncology Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
